The first gene therapies approved to treat sickle cell disease in December 2023 are struggling on the market. But there are ...

Sickle cell anemia (HbSS) is the homozygous dominant variant and the most common and severe form of the disease. Whereas patients who only inherited one gene encoding for abnormal HbS and a different ...

Recent therapies like hydroxyurea (Droxia, Bristol-Myers Squibb), the first FDA-approved drug for SCD in 1994, increase fetal hemoglobin (HbF), which, through unknown pathways, improves SCD symptoms ...

Rapper Lil Poppa, 25, has died, with unverified suicide reports circulating. His death raises concerns due to his battle with sickle cell anemia, which he previously discussed. The cause of death ...

Opportunities in the Sickle Cell Disease market include advancing gene-editing therapies like EDIT-301, expanding VOC-reducing treatments such as inclacumab, and exploring novel drug candidates like ...

Members of Fulcrum management will be joined by Dr. Martin Steinberg, Professor of Medicine, Pediatrics, Pathology and Laboratory Medicine at Boston University Chobanian and Avedisian School of ...

India: A recent multicenter study published in the Indian Journal of Medical Research in September 2025 reports that the ...

Scientists have found that a special component in some people's blood provides them with natural protection against malaria. A recent study has demonstrated that a genetic variant named rs112233623-T ...

People in prisons in Louisiana and across the nation say they're not receiving proper medical care. Why are these cases so common?

Anemia in young adult women is rarely caused by a single factor. Instead, it reflects a layered interaction of nutritional deficiencies, physiological demands, chronic illnesses, genetic ...

Leonard Zon, professor of stem cell and regenerative biology and Grousbeck Professor of Pediatrics at Harvard Medical School, has been awarded the 2026 March of Dimes Richard B. Johnston Jr., MD Prize ...

Detailed price information for Agios Pharmaceuticals (AGIO-Q) from The Globe and Mail including charting and trades.